Mounjaro® (tirzepatide) is an injectable prescription medication developed by Eli Lilly, primarily used to improve blood sugar control in adults with type 2 diabetes when combined with diet and exercise. It also offers significant weight loss benefits, leading to its approval under the brand name Zepbound™ for chronic weight management. The active ingredient, tirzepatide, is a dual GIP and GLP-1 receptor agonist that helps regulate blood sugar and supports weight loss. Mounjaro is available in pre-filled KwikPen® injectors in various strengths, including 2.5 mg/0.5 mL and 5 mg/0.5 mL, among others. Each pen provides once-weekly doses administered subcutaneously. While not suitable for individuals with type 1 diabetes or a history of pancreatitis, common side effects may include nausea, vomiting, diarrhea, decreased appetite, and constipation. It has also been associated with thyroid C-cell tumors in animal studies, though it's unclear if this risk applies to humans. Mounjaro should be used under the supervision of a healthcare provider to ensure safe and effective treatment.